---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-085244"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2022-03-25T23:59:59+00:00"
generated_at: "2026-06-26T17:23:02.581527+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO settles Penn sublicense fees with $8M payment and $12M over 4 years; future fees removed

## Summary
- Company pays $8.0M to Penn for sublicense fees related to AbbVie collaboration agreement.
- Company will pay $12.0M over four years ($3M annually) to satisfy past/future sublicense obligations.
- Letter agreement deletes Section 3.5 of Penn-REGENXBIO License, removing obligation to pay future sublicense fees.
- Penn gains right to conduct gene therapy research outside a single identified field, with no restriction.
- Parties agree to explore further expansion of relationship, including new collaboration and alliance opportunities.

## SEC filing metadata
- accession: 0001193125-22-085244
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2022-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312522085244/0001193125-22-085244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312522085244/d330891d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-085244
- JSON: https://secwatch.observer/filing/0001193125-22-085244.json
- Plain text: https://secwatch.observer/filing/0001193125-22-085244.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.